INTRODUCTION AND OBJECTIVES:
A recent subset analysis of the Prostate, Lung, Colorectal, and Ovarian cancer (PLCO) study has suggested that Finasteride use was associated with a reduced incidence of bladder cancer (HR¼0.634, 95% confidence interval¼0.493-0.816; p ¼ 0.0004). We sought to validate this finding in a multiracial population in our tertiary care center.
METHODS: We identified patients in our institutional database with Benign Prostatic Hyperplasia (BPH) based on International Classification of Diseases (ICD) 9 and 10 codes assigned between 2000 and 2016. From this cohort we then identified patients who were on Finasteride and those that developed bladder cancer. All demographic and clinical variables including age, race, smoking history, finasteride use were collected via an institutional database that prospectively extracts data from electronic medical records (EMR). Finasteride use was based on the documented prescriptions. Chi-square test was used to compare the proportion of bladder cancer patients between two groups (i.e. users and non-users of Finasteride). Multivariate logistic regression analysis was performed to determine the association of finasteride use Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1123
